4.6 Article

Pilot randomized trial of an electronic symptom monitoring and reporting intervention for hospitalized adults undergoing hematopoietic stem cell transplantation

期刊

SUPPORTIVE CARE IN CANCER
卷 28, 期 3, 页码 1223-1231

出版社

SPRINGER
DOI: 10.1007/s00520-019-04932-9

关键词

Symptoms; Electronic symptom reporting; Patient-reported outcomes; Autologous stem cell transplantation; Allogeneic stem cell transplantation; Cancer

资金

  1. National Institutes of Nursing Research [T32 NR00709] Funding Source: Medline
  2. NCI NIH HHS [5K12CA120780-07, K12 CA120780, P30-CA-016086, P30 CA016086] Funding Source: Medline
  3. NCRR NIH HHS [UL1 RR025747] Funding Source: Medline
  4. University Cancer Research Fund [UL1RR025747] Funding Source: Medline

向作者/读者索取更多资源

Purpose Patients undergoing a hematopoietic stem cell transplantation (HCT) have varied symptoms during their hospitalization. This study examined whether daily symptom reporting (with electronic patient-reported outcomes [PROs]) in an inpatient bone marrow transplant clinic reduced symptom burden on post-transplant days +7, +10, and +14. Methods A prospective, single-institution 1:1 pilot randomized, two-arm study recruited HCT patients. HCT inpatients (N = 76) reported daily on 16 common symptoms using the PRO version of the Common Terminology for Adverse Events (PRO-CTCAE). Fisher's exact test was used to examine differences in the proportion of patients reporting individual symptoms. Multivariable linear regression modeling was used to examine group differences in peak symptom burden, while controlling for symptom burden at baseline, age, comorbidity, and transplantation type (autologous or allogeneic). Results HCT patients receiving the PRO intervention also experienced lower peak symptom burden (average of 16 symptoms) at days +7, +10, and +14 (10.4 vs 14.5, p = 0.03). Conclusions Daily use of electronic symptom reporting to nurses in an inpatient bone marrow transplant clinic reduced peak symptom burden and improved individual symptoms during the 2 weeks post-transplant. A multi-site trial is warranted to demonstrate the generalizability, efficacy, and value of this intervention.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据